Winslow Capital Management LLC lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 99.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,197 shares of the medical equipment provider’s stock after selling 11,855,199 shares during the quarter. Winslow Capital Management LLC’s holdings in Boston Scientific were worth $154,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the company. Greenwood Capital Associates LLC lifted its stake in shares of Boston Scientific by 71.7% during the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock valued at $2,671,000 after buying an additional 38,249 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Boston Scientific by 94.9% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock valued at $1,126,000 after buying an additional 18,800 shares in the last quarter. Chevy Chase Trust Holdings Inc. lifted its stake in shares of Boston Scientific by 1.4% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock valued at $34,934,000 after buying an additional 16,992 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Boston Scientific by 3.6% during the 3rd quarter. Legal & General Group Plc now owns 6,760,998 shares of the medical equipment provider’s stock valued at $197,195,000 after buying an additional 232,309 shares in the last quarter. Finally, Beech Hill Advisors Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $353,000. Institutional investors and hedge funds own 87.77% of the company’s stock.
In other news, SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares in the company, valued at approximately $1,029,132. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 193,318 shares of company stock worth $5,088,455. Corporate insiders own 0.74% of the company’s stock.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, hitting the consensus estimate of $0.34. The business had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. equities analysts forecast that Boston Scientific Co. will post 1.37 earnings per share for the current year.
A number of research firms recently weighed in on BSX. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BMO Capital Markets restated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, December 12th. Evercore ISI began coverage on shares of Boston Scientific in a research note on Wednesday, January 3rd. They set an “in-line” rating and a $27.00 target price on the stock. Finally, Jefferies Group restated a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $31.00.
WARNING: “Winslow Capital Management LLC Has $154,000 Stake in Boston Scientific Co. (BSX)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3226354/winslow-capital-management-llc-has-154000-stake-in-boston-scientific-co-bsx.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.